DLH Holdings Corp. (NASDAQ:DLHC) Q3 2022 Results Conference Call August 3, 2022 10:00 AM ET

Company Participants

Chris Witty - IR Advisor

Zach Parker - President and CEO

Kathryn JohnBull - CFO

Conference Call Participants

Joe Gomes - NOBLE Capital

Brian Kinstlinger - Alliance Global Partners

Operator

Good day, and welcome to the DLH Holdings Corp. Fiscal 2022 Third Quarter Earnings Conference Call. [Operator Instructions]

I would now like to turn the conference over to Chris Witty, Investor Relations Advisor.

Chris Witty

Thank you, and good morning, everyone. On the call with me today is Zach Parker, President and Chief Executive Officer; and Kathryn JohnBull, CFO. The company’s earnings release and PowerPoint presentation are available on our website under the Investor page.

I would now like to provide a brief safe harbor statement, which is also shown on Slide 2 of the presentation. This call may include forward-looking statements that relate to the company’s outlook for fiscal 2022 and beyond. These forward-looking statements are subject to various risks and uncertainties that could cause actual results and events to differ materially from these statements. Please refer to the risk factors contained in the company’s annual report on Form 10-K and in our other filings with the Securities and Exchange Commission. We do not undertake any duty to update any forward-looking statements.

On today’s call, we will be referencing both GAAP and non-GAAP financial measures. A reconciliation of our non-GAAP results to our reported GAAP results is included in our earnings release and in the investor presentation on DLH’s website. President and CEO, Zach Parker, will speak next; followed by CFO, Kathryn JohnBull, after which we’ll open it up for questions.

And with that, I’d now like to turn the call over to Zach Parker.

Zach Parker

Thank you, Chris, and good morning, everyone. Welcome to our fiscal 2022 third quarter conference call. I am pleased to report yet another solid quarter, particularly as we wind down our two major COVID-19 pandemic response programs; one with the FEMA, Alaska counter-measures and the NIH Infectious Disease Clinical Trials for Therapeutics. Both of these programs demonstrated DLH’s ability to surge and provide a rapid response to national threats, leveraging our emergency preparedness and global clinical research network capabilities.

Beginning with Slide 3, I’ll first provide a high level overview of the quarter, starting with the top-line results. Revenue rose nearly 8% year-over-year to $66.4 million, reflecting strong demand across many of our programs and services. We are very pleased with the recent award activity and a large number of ongoing opportunities within the company, particularly as we approach the end of 2022 and we’ll soon be launching into FY ‘23. I’ll discuss the outlook more in a moment.